✦ LIBER ✦

Extracapsular radiation dose annulus correlates with biochemical control in low-risk brachytherapy patients: Results of a prospective randomized trial

✍ Scribed by Gregory S. Merrick; Wayne M. Butler; Kent E. Wallner; Zachariah A. Allen; Brian C. Kurko; Richard L. Anderson; Robert Grammer; Robert W. Galbreath

Book ID: 108074734
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 64 KB
Volume: 5
Category: Article
ISSN: 1538-4721
DOI: 10.1016/j.brachy.2006.03.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiation Dose Predicts for Biochemical

Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy

✍ Alice Y. Ho; Ryan J. Burri; Jamie A. Cesaretti; Nelson N. Stone; Richard G. Stoc 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 320 KB

Efficacy and safety of high-dose pravast

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

✍ James H. Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a place

Impact of age on biochemical control in

Impact of age on biochemical control in a cohort of intermediate- and high-risk prostate cancer patients treated with high-dose-rate brachytherapy boost combined with pelvic external beam radiation therapy

✍ Amy L. Limbacher; Michel Ghilezan; Gary Gustafson; Peter Y. Chen; Christine Mitc 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Early versus late intensification for pa

Early versus late intensification for patients with high-risk Hodgkin lymphoma—3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation : Five-year results of a randomized trial on behalf of the GOELAMS group

✍ Nina Arakelyan; Christian Berthou; Bernard Desablens; Sophie de Guibert; Vincent 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views